

LACHMAN CONSULTANT SERVICES, INC.
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590
(516) 222-6222 • FAX (516) 683-1887

2013 JUL -3 A 11:15

July 2, 2013

OVERNIGHT COURIER 07/02/13

Division of Dockets Management
Food and Drug Administration (HFA-305)
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Citizen Petition

Dear Sir or Madam:

The undersigned submits this petition, in quadruplicate, pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 C.F.R. § 10.30 on behalf of a client requesting the Commissioner of the Food and Drug Administration to declare that the drug products, Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4 mg/300 mg, 6 mg/300 mg, and 8 mg/300 mg are suitable for consideration in an abbreviated new drug application (ANDA).

A. Action Requested

The petitioner requests that the Commissioner of the Food and Drug Administration declare that Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4 mg/300 mg, 6 mg/300 mg, and 8 mg/300 mg are suitable for submission as an ANDA. The reference listed drug products (RLDs), upon which this petition is based are as follows:

Application Number	Drug Product; Strength	Applicant
ANDA No. 040658	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg	Mikart
ANDA No. 040556	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/300 mg	Mikart
ANDA No. 040556	Hydrocodone Bitartrate and Acetaminophen Tablets USP, 10 mg/300 mg	Mikart

Therefore, the petitioner seeks a change in strength of the hydrocodone bitartrate component from that of the listed drug products from 5 mg to 4 mg, from 7.5 mg to 6 mg, and from 10 mg to 8 mg.

B. Statement of Grounds

The Federal Food, Drug and Cosmetic Act provides for the submission of an ANDA for a drug product that differs in dosage strength from that of the listed drug provided the FDA has approved a petition that proposed filing such an application.

The RLDs, Hydrocodone Bitartrate and Acetaminophen USP, by Mikart are tablet products containing 300 mg of acetaminophen in combination with 5 mg, 7.5 mg or 10 mg of hydrocodone bitartrate. See product listing for ANDA 040556 and ANDA 040658 from the electronic Orange Book also known as the

Approved Drug Products with Therapeutic Equivalence Evaluations, accessed July 1, 2013, which reflects the approval of these RLDs. (Attachment 1). The proposed drug products also represent a tablet dosage form containing 300 mg of acetaminophen, but in combination with 4 mg, 6 mg, or 8 mg of hydrocodone bitartrate. This petition is thus seeking a change in strength of only the hydrocodone bitartrate component from that of the RLDs.

These proposed strengths of Hydrocodone Bitartrate in combination with Acetaminophen will provide healthcare practitioners with additional dosing options to precisely meet the patient's pain relief needs. At the same time, these new strengths offer healthcare practitioners the ability to titrate the patient to the lowest dose necessary to achieve the desired response, and thereby reduce the patient's exposure to the narcotic component in this combination drug product.

In addition, please note that the proposed dosage strengths are consistent with the dosing recommendations of the RLD's approved labeling. The current dosing instructions in the approved labeling of the RLDs are as follows:

"Dosage should be adjusted according to the severity of the pain and the response of the patient. However, it should be kept in mind that tolerance to hydrocodone can develop with continued use and that the incidence of untoward effects is dose related.

Xodol^{®1} 5/300 (Hydrocodone Bitartrate and Acetaminophen Tablets, USP 5 mg/300 mg): The usual adult dosage is one or two tablets every four to six hours as needed for pain. The total daily dosage should not exceed 8 tablets.

Xodol[®] 7.5/300 (Hydrocodone Bitartrate and Acetaminophen Tablets, USP 7.5 mg/300 mg): The usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.

Xodol[®] 10/300 (Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/300 mg): The usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets."

Thus, the hydrocodone bitartrate dosage ranges from a minimum of 20 mg per day (one 5 mg/300 mg tablet every six hours) to a maximum of 60 mg per day (six 10 mg/300 mg tablets per day). Mikart's package insert for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg, and 10 mg/300 mg is included in Attachment 2.

Similarly, the dosage for the proposed products, as illustrated in the enclosed draft labeling (Attachment 3) would be as follows:

"Hydrocodone Bitartrate and Acetaminophen Tablets, USP 4 mg/300 mg: The usual adult dosage is one or two tablets every four to six hours as needed for pain. The total daily dosage should not exceed 8 tablets.

¹ The FDA's Orange Book does not list the proprietary name, "Xodol", in connection with Mikart's Hydrocodone Bitartrate and Acetaminophen drug products. However, the products are drug listed in FDA's NDC Directory under the Xodol proprietary name and reference Mikart's ANDA Nos. 040658 (Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg) and 040556 (Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/300 mg and 10 mg/300 mg).

Hydrocodone Bitartrate and Acetaminophen Tablets, USP 6 mg/300 mg: The usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.

Hydrocodone Bitartrate and Acetaminophen Tablets, USP 8 mg/300 mg: The usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets."

The proposed products will therefore offer Hydrocodone Bitartrate dosages in a range from 16 mg per day (one 4 mg/300 mg tablet every six hours) to a maximum of 48 mg per day (six 8 mg/300 mg tablets per day). These dosages are consistent with the dosing recommendations and allowances approved in the reference listed drug products' labeling and offer additional options for titrating patients to the lowest effective dose of Hydrocodone Bitartrate and Acetaminophen combination drug product to achieve pain relief.

In summary, the proposed changes in strength of the Hydrocodone Bitartrate component from that of the reference listed drugs will not raise questions of safety or efficacy for the proposed products. The indication remains unchanged, and the proposed dosing is consistent with that recommended in the labeling of the approved reference listed drug products. Therefore, the Agency should conclude that clinical investigations are not necessary to demonstrate the proposed products' safety or effectiveness.

There are no proposed changes in labeling, with the exception of the obvious changes in strength sought in this petition. The uses, indications, warnings, and directions for use will remain the same as that of the RLDs. As previously noted, draft labeling for the proposed products is included in Attachment 3.

Therefore, the petitioner's request for the Commissioner to find that the changes in strength of Hydrocodone Bitartrate in the proposed Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4 mg/300 mg, 6 mg/300 mg, and 8 mg/300 mg, should raise no questions of safety or effectiveness, and the Agency should approve the petition.

Inapplicability of the Pediatric Research Equity Act ("PREA"). PREA, which is codified at FDC Act § 505B, does not apply to a new strength, such as the one proposed in this Petition. (See FDC Act § 505B(a)(1)(A)). As such, PREA should not serve as an impediment to the Agency's granting of this Petition.

C. Environmental Impact

The petitioner claims a categorical exclusion under 21 CFR 25.31.


D. Economic Impact

The petitioner does not believe that this is applicable in this case, but will agree to provide such an analysis if requested by the Agency.

E. Certification

The undersigned certifies, that to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner, which are unfavorable to the petition.

Respectfully submitted,


Joan Janulis, R.A.C.
Vice President

JJ/ly

Attachments:

1. Approved Drug Products with Therapeutic Equivalence Evaluations, Electronic Orange Book listing accessed July 1, 2013
2. Labeling for reference listed drug products (RLDs), Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg, and 10 mg/300 mg (Mikart), updated June 2011.
3. Draft Insert Labeling Proposed for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 4 mg/300 mg, 7.5 mg/300 mg, and 10 mg/300 mg.

cc: Martin Shimer (OGD)

Petition Hydrocodone_apap 070213

11/2/13

FedEx Ship Manager - Print Your Label(s)

From: (516) 683-1881
Westbury Office
LACHMAN CONSULTANT SERVICES
1600 STEWART AVE
SUITE 604
WESTBURY, NY 11590

Origin ID: RMEA



J13111302120026

SHIP TO: (301) 827-6860

BILL SENDER

Division of Dockets Management
FDA, DHHS, HFA-305
5630 FISHERS LN RM 1061

ROCKVILLE, MD 20852

Ship Date: 02JUL13

ActWgt: 1.5 LB

CAD: 105332656/MNET3370

Delivery Address Bar Code



Ref # Citizen Petition
Invoice #
PO #
Dept #



WED - 03 JUL 3:00P
STANDARD OVERNIGHT

TRK# 7961 4870 9054

0201

DSR
20852
MD-US
IAD

XC NSFA



518G1/AQ493AB